BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Investor Presentation (September 2022)

26 slides from BioRestorative Therapies's investor presentation, September 2022

  1. Slide 1: Nloneein watts

    Nloneein watts therapies

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY”) THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INFORMATION WITH

  3. Slide 3: Leadership

    LEADERSHIP LANCE ALSTODT ROBERT KRISTAL FRANCISCO SILVA Chairman & CEO Chief Financial Officer Vice President of R&D Lance leads BRTX’s mission to Robert has a versatile background Francisco has over 20 years of improve the lives of patients through of over 25 years on Bay Street and experience in t

  4. Slide 4: Company Highlights

    COMPANY HIGHLIGHTS Disruptive Platform Technologies in Cellular Therapy Strong Preliminary Data Indicative of Positive Trial Outcomes Active Phase 2 Trial in Spine Addressing Multi-Billion Dollar Markets with Unmet Needs Opportunity for Key Strategic Partnerships Multiple Near-Term Value Enhancing I

  5. Slide 5: A Platform Technology

    A Platform Technology Preclinical Phase 1 Phase 2 Phase 3 Spine Lumbar Cervical Autologous Thoracic Musculoskeletal System Hips/Knees Extremities Avascular Zones Metabolic Type 2 Diabetes Obesity Allogeneic PCOS Brown Adipose Stem Cells ARDS Long Hauler Covid Gene Modification BRTX 200 Polymer/Crisp

  6. Slide 6: Chronic Lumbar Disc Disease Program – Phase 2

    CHRONIC LUMBAR DISC DISEASE PROGRAM – PHASE 2 • Lead investigational therapeutic product • Autologous (patient’s own) cell-based biologic • Hypoxic (low oxygen) cultured, bone marrow-derived • Single intradiscal injection – anticipated 30 minute in-office procedure DISC/SPINE • Prior human data prov

  7. Slide 7: Market Opportunity – BRTX-100

    MARKET OPPORTUNITY – BRTX 100 258 MILLION American adult population American adults with chronic lower back 64.5 MILLION pain prevalence 32 MILLION American adults with diagnosed and treated disc degeneration 15 MILLION Americans have pain caused by a protruding or injured disc 2.5 MILLION Invasive

  8. Slide 8: Standard of Care: Clinical and Economic Problem

    STANDARD OF CARE: CLINICAL AND ECONOMIC PROBLEM CONSERVATIVE TREATMENTS SURGICAL TREATMENTS OFTEN RECURRENT WITH RE-OP RATES OFTEN 10-20% ORAL MEDICATION TREATMENT SIMPLE ELEGANT SOLUTION SPINAL FUSION SURGERY $1,000 - $2,000 INTRODUCE HYPOXIC CULTURED Annually AUTOLOGOUS MSCs $110,000 1, 5 INJECTIO

  9. Slide 9: Logistical/Clinical Process

    LOGISTICAL/CLINICAL PROCESS 1 Shipping 3 Shipping 5 Cryoport Cryoport . Bone marrow and Sample shipped at BRTX-100® BRTX-100® shipped Intradiscal delivery blood collected ambient to Manufactured, and frozen to clinical site of BRTX-100® from subject. BioRestorative QC released Therapies Clinical Sit

  10. Slide 10: Positive Human Data

    POSITIVE HUMAN DATA Human data from studies of therapies similar to brtx-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response. 10

  11. Slide 11: Defined Health Report

    DEFINED HEALTH REPORT In May 2018, Defined Health (a bio-consulting company) conducted a company sponsored blinded study with relevant key opinion leaders to provide an independent review of BRTX-100 Key Findings Include: Stem-cell therapies have “great potential” to treat cLDD (and related therapeu

  12. Slide 12: Trial Design

    TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with CLDD Study Design and Patient Population • Study includes 99 subjects (2:1 product to placebo) • 40.000.000 cells/dose • Included subjects will have only one symptomatic diseased disc • Primary efficacy

  13. Slide 13: Trial Design: Primary and Secondary Endpoints

    TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with CLDD Primary and Secondary Endpoints: Primary Efficacy Endpoint: The primary efficacy endpoint is clinical response, defined as at least a 30% decrease in pain as measured on the VAS scale and at least a

  14. Slide 14: Competitive Landscape Key Differentiating Factors

    COMPETITIVE LANDSCAPE KEY DIFFERENTIATING FACTORS BRTX-100 ADVANTAGES: • Autologous cells means low to no risk of rejection, Normoxic cultured – with greater safety profile (introduction of viral/genetic), Hypoxic cultured – in low potentially streamlined regulatory path normal oxygen environment ox

  15. Slide 15: Autologous Platform

    AUTOLOGOUS PLATFORM MULTIPLE OPPORTUNITIES BRTX 100 is a platform technology with multiple applications First Indication is cLDD currently approved for a Phase 2 Clinical Study Near term opportunities to leverage platform across other avascular zones Stem Cell processing and management opportunities

  16. Slide 16: Metabolic Program

    METABOLIC PROGRAM THERMOSTEM PROGRAM “Off the shelf” allogeneic cell-based therapy targeted to treat obesity, Type 2 diabetes and metabolic disorders using brown fat stem cells Brown fat has been shown to regulate metabolic homeostasis in the body Large library of human brown adipose tissue (BAT), w

  17. Slide 17: Metabolic Program Highlights

    METABOLIC PROGRAM HIGHLIGHTS First human stem cell derived BAT transfer Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) Successful delivery of 3D aBAT construct in mouse model Transplantation of aBAT lowered blood glucose levels Transplantation of aBAT decrease

  18. Slide 18: Metabolic Program Clinical Timeline

    METABOLIC PROGRAM CLINICAL TIMELINE 2022 2023 2023/2024 Pre-IND Initiate File DMF Meeting Phase 1/2 with FDA with FDA Clinical Trial Expected filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities Schedule pre-IND (Investigational New Drug) meeting with FDA to discuss f

  19. Slide 19: Intellectual Property

    INTELLECTUAL PROPERTY PROGRAM: PROGRAM: DISC/SPINE METABOLIC (THERMOSTEM) PATENT TITLES PATENT TITLES • Methods and Compositions to facilitate repair • Brown Fat Compositions and Methods of avascular tissue • Human Brown Adipose Derived Stem Cells and Uses • Surgical Methods and Compositions to • No

  20. Slide 20: Near-Term Goals

    NEAR-TERM GOALS Q1 2022 Announce Contracts with Clinical Research Organization (CRO) Announce opening of Cell cGMP Manufacturing Facility Q2 Filings of New BRTX-100 Patents 2022 Product Manufacturing Clearance Clinical Sites Established for Disc Trial Complete BRTX-100 Engineering Runs Q3 First Pati

  21. Slide 21: Company Highlights

    COMPANY HIGHLIGHTS Disruptive Platform Technologies in Cellular Therapy Strong Preliminary Data Indicative of Positive Trial Outcomes Active Phase 2 Trial in Spine Addressing Multi-Billion Dollar Markets with Unmet Needs Opportunity for Key Strategic Partnerships Multiple Near-Term Value Enhancing I

  22. Slide 22: Financial Summary

    FINANCIAL SUMMARY Current Capitalization Shares Basic Shares Outstanding 3,645,886 Cash on Hand $17.9 MILLION Debt $0 Sufficiently funded for Ph2 BRTX-100 TRIAL Data as of Q2 2022 22

  23. Slide 23: BioRestorative Upcoming Milestones/Catalysts

    BioRestorative Upcoming Milestones/Catalysts Events Timing Outcome • Recommend patients continue in the study Q1/2023 Safety Data Read out • Enablable acceleration of enrollment DSMD • Validate Safety Profile/ Program Approach Ongoing • Continue to announce prestigious sites and Site Enrollment / An

  24. Slide 24: Scientific Advisory Board

    SCIENTIFIC ADVISORY BOARD Wayne Marasco, M.D., Ph.D. is a principal faculty member of Harvard Stem Cell Institute as well as a Professor in the WAYNE MARASCO, MD, PhD Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Chairman of SAB Med

  25. Slide 25: Leadership

    LEADERSHIP Lance Alstodt Francisco Silva Robert Kristal Chairman & CEO Vice President of R&D CFO Lance Alstodt joined BioRestorative Therapies as its Francisco Silva joined BRT in April 2011 and is Vice President Mr. Kristal is an experienced and versatile professional Chairman and Chief Executive O

  26. Slide 26: orectoncive

    orectoncive therapies

BioRestorative Therapies — Investor Presentation (September 2022) on 6ix